Trial · NCT06043674
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
NCT06043674, Phase 2, Recruiting, Christine Ryan
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation. Trials, record NCT06043674. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06043674
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
- NCT number
- NCT06043674
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Christine Ryan
- Conditions
- Chronic Lymphocytic Leukemia, Richter's Transformation
- Interventions
- Glofitamab, Obinutuzumab, Polatuzumab Vedotin, Atezolizumab, Tocilizumab, Pirtobrutinib
- First posted
- 2023-09-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Best Complete Response (CR) Rate | Disease evaluation will be performed at 12, 24 and 36 weeks | Best Complete Response (CR) rate is defined as the proportion of participants achieving CR at any of the 3 timepoints (after 4, 8 and 12 cycles). CR is defined per Lugano 2014 criteria. |
| Secondary | Best Overall Response Rate (ORR) | Disease evaluation will be performed at 12, 24 and 36 weeks | Best Overall response rate (ORR) is defined as the proportion of participants achieving complete response (CR) or partial response (PR) at any of the 3 timepoints (after 4, 8 and 12 cycles). CR and PR are defined per Lugano 2014 criteria. |
| Secondary | Best Partial Response (PR) Rate | Disease evaluation will be performed at 12, 24 and 36 weeks | Best Partial response (PR) rate is defined as the proportion of participants achieving partial response at any of the 3 timepoints (after 4, 8, 12 cycles). PR is defined per Lugano 2014 criteria. |
| Secondary | Overall Response Rate at 36 weeks | 36 weeks | Overall response rate (ORR) at 36 weeks is defined as the proportion of participants who achieve complete response (CR) or partial response (PR) at the time of disease evaluation at 12 cycles (36 weeks). CR and PR are defined per Lugano 2014 criteria. |
| Secondary | Partial Response (PR) Rate at 36 weeks | 36 weeks | Partial Response (PR) rate at 36 weeks is defined as the proportion of participants achieving PR at the time of disease evaluation at 12 cycles (36 weeks). PR defined per Lugano 2014 criteria. |
| Secondary | Complete Response (CR) Rate at 36 weeks | 36 weeks | Complete Response (CR) rate at 36 weeks is defined as the proportion of participants achieving CR at the time of disease evaluation at 12 cycles (36 weeks). CR defined per Lugano 2014 criteria. |
| Secondary | Duration of Response (DOR) | Disease evaluation will be performed every 3 months, up to 2 years. | Duration of Response (DOR) is defined as the time from date of first documented confirmed objective response (CR + PR) to date of first documented progressive disease (PD) per Lugano 2014 criteria. |
| Secondary | Duration of Complete Response (DOCR) | In long-term follow-up, participants were assessed every 6 months, up to 2 years | Duration of complete response (DOCR) is defined as the time from date of first documented complete response to date of first documented progressive disease (PD) per Lugano 2014 criteria. |
| Secondary | Progression Free Survival (PFS) at 2 years | Participants will be followed up to 2 years. | PFS at 2 years is the percent probability estimate at 2 years based on the Kaplan-Meier method. PFS will be calculated as the time from start of treatment to the date of progressive disease (PD, defined per Lugano 2014 criteria), death, or last follow-up. Participants alive and progression-free at time of last follow-up will be censored. |
| Secondary | Median Progression Free Survival (PFS) | Participants will be followed up to 2 years. | PFS will be calculated as the time from start of treatment to the date of progressive disease (PD, defined per Lugano 2014 criteria), death, or last follow-up. Participants alive and progression-free at time of last follow-up will be censored. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06043674
GET https://conductscience.org/api/trials/v1/NCT06043674/registered